#24 of the S&P 500: Gilead Sciences, Inc. (NASDAQ:GILD)
Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Co.'s portfolio of products include: human immunodeficiency virus/ acquired immune deficiency syndrome, which includes Stribild®, Complera®/Eviplera®, Atripla®, Truvada®, Viread®, and Emtriva®; liver disease, which includes Viread® and Hepsera®; cardiovascular, which includes Letairis®, Ranexa®, and Lexiscan/Rapiscan®; Respiratory, which includes Cayston® and Tamiflu; and other, which includes AmBisome®, Vistide® and Macugen. Co. has operations in North America, Europe and Asia. Open the GILD Page at The Online Investor »
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Service. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20
minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.